Expression of WW domain-containing oxidoreductase in osteosarcoma tissues and its effect on proliferation and metastasis of osteosarcoma cells
张翼,许峰,闻嘉,李哲,李家平,卢新昌,刘永奎,谢祎,王帝,张卫红,李甲振,张岩,李隆卿,元耀博
DOI: https://doi.org/10.3760/cma.j.cn421213-20200905-01304
2021-01-01
Abstract:Objective:To study the correlation between WW domain-containing oxidoreductase (WWOX) expression and clinicopathological features of osteosarcoma, and explore the effect of WWOX on the proliferation and metastasis of human osteosarcoma in mice.Methods:The expression of WWOX in osteosarcoma tissues was detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry. The correlation between the WWOX expression and clinicopathological features of osteosarcoma was evaluated. The osteosarcoma cells 143B were injected into the tibias of immunodeficient mice to establish the osteosarcoma xengrafted model. Lentivirus, lentivirus-delivered WWOX and lentivirus-delivered WWOX short hairpin RNA (shRNA) were injected into tumor respectively. The tumor growth was recorded and compared. The number of pulmonary nodules was assessed using micro CT. For the measurement data that conform to the normal distribution, the independent sample t test was used for difference analysis; for the measurement data that do not conform to the normal distribution, the nonparametric test was used for difference analysis; for the grade data, the nonparametric test was used for difference analysis; for the count data, the test was used for difference analysis. The differences between different groups were analyzed by one-way ANOVA.Results:There was no significant correlation between WWOX expression and some clinicopathological features, including gender, age, primary site, etc. The high WWOX expression was correlated with low microvascular density (MVD) and small tumor volume. The overall survival (OS) and disease-free survival in patients with high WWOX expression was obviously longer than those of patients with low WWOX expression. The growth rate of primary tumor in immunodefient mice was significantly lower in WWOX group and significantly higher in WWOX shRNA group than in vector group. The number of pulmonary nodule was significantly greater in WWOX shRNA group than in vector group. However, there was no significant difference in the number of pulmonary nodule between WWOX group and vector group. WWOX was expressed in a higher level in primary tumor in WWOX group and lower level in WWOX shRNA group than in vector group. WWOX was expressed in the lower level in pulmonary nodule in WWOX shRNA group than in vector group. MVD was expressed in a lower level in primary tumor in WWOX group and higher level in WWOX shRNA group than in vector group. MVD was expressed in the higher level in pulmonary nodule in WWOX shRNA group than in vector group. However, there was no significant difference in WWOX level and MVD between WWOX group and vector group. We further found that WWOX could regulate the expression of proliferation cell nuclear antigen (Ki-67) and matrix metalloproteinase (MMP)-2 through extracellular signal-regulated kinase (ERK) phosphorylation, and further regulate the proliferation and invasion of osteosarcoma.Conclusion:The high expression of WWOX is associated with better prognosis in osteosarcoma. WWOX can inhibit the growth of tumor bearing osteosarcoma in mice with immunodeficiency through ERK signaling pathway, and inhibit the angiogenesis and lung metastasis of tumor bearing osteosarcoma in mice with immunodeficiency.